Ketoconazole Tablets Rx
Generic Name and Formulations:
Various generic manufacturers
Indications for Ketoconazole Tablets:
Susceptible systemic fungal infections (blastomycosis, coccidioidomycosis, histoplasmosis, chromomycosis, paracoccidioidomycosis) in those who have failed or are intolerant to other therapies. Do not use for fungal meningitis.
Initially 200mg daily; max 400mg daily. Usual duration: 6 months.
<2yrs: not studied. >2yrs: see full labeling.
Concomitant dofetilide, quinidine, pimozide, cisapride, methadone, disopyramide, dronedarone, ranolazine, felodipine, nisoldipine, tolvaptan, irinotecan, lurasidone, alprazolam, oral midazolam, oral triazolam, eplerenone, ergot alkaloids, simvastatin, lovastatin, colchicine. Acute or chronic liver disease.
Should be used only when other effective antifungal therapy is not available or tolerated. Risk of serious hepatotoxicity; monitor closely. Obtain SGGT, ALT/AST, bilirubin, alkaline phosphatase, PT, INR, viral hepatitides at baseline. Monitor ALT weekly during therapy; if ALT is >30% baseline or symptoms develop, interrupt and perform full liver function tests. QT prolongation. Monitor adrenal function in adrenal insufficiency, borderline adrenal function, or under prolonged stress. Children. Pregnancy (Cat.C). Nursing mothers: not recommended.
See Contraindications. QT prolongation with concomitant dofetilide, quinidine, pimozide, cisapride, methadone, disopyramide, dronedarone, ranolazine. Concomitant sirolimus, everolimus, temsirolimus, tamsulosin, rifabutin, rivaroxaban, salmeterol, dasatinib, lapatinib, nilotinib: not recommended. Potentiates alfentanil, sufentanil, fentanyl, buprenophine, oxycodone, calcium channel blockers, bosentan, buspirone, carbamazepine, cilostazol, cyclosporine, digoxin, oral anticoagulants, indinavir, saquinavir, sildenafil, vardenafil, tadalafil, tacrolimus, telithromycin, atorvastatin, tolterodine, trimetrexate, verapamil, vinca alkaloids, bortezomib, busulphan, docetaxel, erlotinib, imatinib, ixabepilone, paclitaxel, aripiprazole, quetiapine, ramelteon, risperidone; monitor and adjust doses. Avoid alcohol or other hepatotoxic drugs. Antagonized by carbamazepine, efavirenz, nevirapine, phenytoin, rifabutin, isoniazid, rifampicin: not recommended. Potentiated by CYP3A4 inhibitors (eg, ritonavir, ritonavir/darunavir, ritonavir/fosamprenavir); adjust ketoconazole dose as needed. Separate dosing of acid neutralizing drugs (eg, aluminum hydroxide) by at least 1hr before or 2hrs after ketoconazole; should give with acidic beverage (eg, non-diet cola). Caution with concomitant repaglinide, saxagliptin, praziquantel, maraviroc, H2-blockers, PPIs, and eletriptan (do not use within 72hrs of ketoconazole). Monitor digoxin, phenytoin, carbamazepine, oral anticoagulants. Consider reducing concomitant dabigatran dose in moderate renal impairment.
Nausea, vomiting, abdominal pain, urticaria, pruritus, insomnia, nervousness, CNS disorders, photophobia, orthostatic hypotension, myalgia, menstrual disorder, asthenia, fatigue, hot flush, malaise, edema peripheral, pyrexia, chills; hepatotoxicity, anaphylaxis, decreased testosterone levels, Torsades de pointes (may be fatal).
Formerly known under the brand name Nizoral.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Managing Immune-Related Adverse Events
- PD-1/PD-L1 Inhibitors May Increase the Risk of Hyperprogressive Disease in NSCLC
- Oncology Community Expresses Concern About Medicare Advantage Step-Therapy Policy
- Progressive Telomere Shortening: An Epigenetic Biomarker of Chronic Myeloid Leukemia
- Predicting Response to Immunotherapy in Late-Stage Melanoma
- Two Independent Variables Found to Be Prognostic in Diffuse Large B-Cell Lymphoma
- Genetic Counseling Recommended for Advanced Prostate Cancer
- Feasibility of Clinical Production of Autologous NKG2D CAR-T
- A Simplified Dose Schedule of Cetuximab as a Maintenance Therapy in Head and Neck Cancer May Reduce Drug Toxicities
- Managing Immune-Related Adverse Events